Our subsidiary, BioSymetrics, has initiated a collaboration focused on CDKL5 Deficiency Disorder (CDD), a rare genetic epilepsy. It is working with BrainStorm Therapeutics and academic collaborators to discover and validate therapeutic candidates. #CDKL5 #RareEpilepsy #DrugDiscovery